1. ITIH5 and ECRG4 DNA Methylation Biomarker Test (EI-BLA) for Urine-Based Non-Invasive Detection of Bladder Cancer
- Author
-
Susanne Füssel, Ruth Knüchel, Laura Godfrey, Christian Bach, Manja U. Böhme, Alexander Herr, David Fiedler, Edgar Dahl, Sarah Bringezu, Doreen Hübner, David Pfister, Jörg Ellinger, Manfred P. Wirth, Nadine T. Gaisa, Maximilian Koch, and Michael Rose
- Subjects
Oncology ,medicine.medical_specialty ,ECRG4 ,Urinary system ,Urine ,Article ,Catalysis ,Inorganic Chemistry ,lcsh:Chemistry ,Internal medicine ,bladder cancer detection ,medicine ,ITIH5 ,urinary biomarkers ,Physical and Theoretical Chemistry ,Molecular Biology ,lcsh:QH301-705.5 ,Spectroscopy ,Bladder cancer ,DNA methylation ,business.industry ,Organic Chemistry ,Non invasive ,General Medicine ,Methylation ,medicine.disease ,Computer Science Applications ,Restriction enzyme ,lcsh:Biology (General) ,lcsh:QD1-999 ,Biomarker (medicine) ,business - Abstract
Bladder cancer is one of the more common malignancies in humans and the most expensive tumor for treating in the Unites States (US) and Europe due to the need for lifelong surveillance. Non-invasive tests approved by the FDA have not been widely adopted in routine diagnosis so far. Therefore, we aimed to characterize the two putative tumor suppressor genes ECRG4 and ITIH5 as novel urinary DNA methylation biomarkers that are suitable for non-invasive detection of bladder cancer. While assessing the analytical performance, a spiking experiment was performed by determining the limit of RT112 tumor cell detection (range: 100&ndash, 10,000 cells) in the urine of healthy donors in dependency of the processing protocols of the RWTH cBMB. Clinically, urine sediments of 474 patients were analyzed by using quantitative methylation-specific PCR (qMSP) and Methylation Sensitive Restriction Enzyme (MSRE) qPCR techniques. Overall, ECRG4-ITIH5 showed a sensitivity of 64% to 70% with a specificity ranging between 80% and 92%, i.e., discriminating healthy, benign lesions, and/or inflammatory diseases from bladder tumors. When comparing single biomarkers, ECRG4 achieved a sensitivity of 73%, which was increased by combination with the known biomarker candidate NID2 up to 76% at a specificity of 97%. Hence, ITIH5 and, in particular, ECRG4 might be promising candidates for further optimizing current bladder cancer biomarker panels and platforms.
- Published
- 2020
- Full Text
- View/download PDF